A Phase III Randomized, Active-comparator-Controlled Clinical Trial to Study the Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator, in Subjects 3 Months to <12 Years of Age with Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Trial Profile

A Phase III Randomized, Active-comparator-Controlled Clinical Trial to Study the Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator, in Subjects 3 Months to <12 Years of Age with Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Oct 2017

At a glance

  • Drugs Tedizolid (Primary) ; Cefalexin; Cefazolin; Clindamycin; Clindamycin; Flucloxacillin; Flucloxacillin; Linezolid; Linezolid; Vancomycin
  • Indications Bacterial infections; Skin and soft tissue infections
  • Focus Adverse reactions
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 12 Sep 2017 Planned End Date changed from 18 Sep 2020 to 24 Feb 2021.
    • 12 Sep 2017 Planned primary completion date changed from 18 Aug 2020 to 26 Jan 2021.
    • 12 Sep 2017 Planned initiation date changed from 2 Apr 2018 to 15 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top